The Biden Administration has been slow to implement sanctions under the Uyghur Human Rights Policy Act, which became law in 2020, and seeks to hold the perpetrators of the Uyghur genocide accountable. U.S. Senator Marco Rubio (R-FL) and U.S. Representative Mike...
In-person Mobile Office Hours Monday, December 11, 2023 Jackson County 9:30am – 11:00am CST UF/IFAS Jackson County Extension 2741 Penn Ave. Suite 3 Marianna, FL 32448 Click Here Pinellas County 1:30pm – 3:00pm EST Pinellas Park Chamber of Commerce 5851 Park...
Foreign adversaries, including China, have significantly increased covert tactics to infiltrate American colleges and K-12 schools. They do this to steal research, spread propaganda, and silence students and academics. U.S. Senator Marco Rubio (R-FL) and...
The criminal Maduro regime issued bogus warrants to arrest members of the Venezuelan opposition, including several campaign staffers working for opposition leader María Corina Machado, who won the opposition’s primary election earlier this year. Last night, Roberto...
El senador estadounidense Marco Rubio (R-FL) habló con Ninoska Pérez en La Poderosa 670 AM, sobre los grupos en EE.UU. que apoyan la masacre que lidera Hamás contra Israel, sobre los reclamos para un cese de fuego, sobre el arresto de Manuel Rocha y más. Una...
Yes, We Should Restrict U.S. Investment in China U.S. Senator Marco Rubio (R-FL) December 7, 2023 National Review [A] recent investigation reveals that U.S. firm BlackRock is funneling the assets of millions of unwitting Americans into Chinese companies directly...
ICYMI: Rubio To FDA: Don’t Yank Hope From Dying Children
Don’t Yank Hope From Dying Children
By Marco Rubio
May 9, 2016
The last couple of weeks have brought about an extraordinary display of strength from thousands of patients, parents, doctors, and friends on behalf of those with a rare disease called Duchenne muscular dystrophy, which causes a steady deterioration of muscle mass. By age 12, most boys with Duchenne have lost the ability to walk. The average life expectancy is about 25 years.
Last month, scores of these advocates flew to Washington, D.C., from around the country to attend a hearing of an FDA advisory committee that was set to rule on the viability of a promising new drug to treat Duchenne.
This committee was evaluating the results of a clinical trial of the drug that was conducted among a small group of people who have this disease. Those taking the drug have widely reported that it helped slow Duchenne’s progression and even led to some improvements in quality of life. This FDA advisory panel was meeting to decide whether to allow testing to expand and this drug to be more widely available.
They heard from an entire community of parents whose kids have Duchenne, who are seeing them improve, who know these kids better than any scientist, any doctor, any panelist at the FDA — and who begged for the drug to be approved. The committee, sadly, ruled against the drug. It did so because it essentially applied the same standard to this drug as it would to one designed to treat a much more common disease.
The committee should have instead focused on reviewing the drug in the context of a law passed in 2012 called the Food and Drug Administration Safety and Innovation Act, or FDASIA. It included multiple provisions to address the challenges of the rare disease patient community. In addition to having far fewer potential participants for drug studies, many rare diseases such as Duchenne are also 100 percent fatal, which means there are ethical concerns with giving any participant in a study a placebo.
One of the committee members who voted against the drug was later quoted as saying, “Based on all I heard, the drug definitely worked, but the question was framed differently.”
The FDA posed the question to this committee not by asking if the drug worked or not, but by asking about the process of the clinical trial. Did it have enough people? Was it conducted in the normal way? The drug’s trial, of course, did not meet the FDA’s normal standards, but only because it was not treating a normal condition.
Had the FDA utilized the various tools and authorities FDASIA grants to them to ease the evaluation of rare disease treatments, the committee very well may have reached a different conclusion. Instead, these patients and families are on the verge of losing access to the drug.
Keep reading here.